Loading
EPCORE NHL-1 was the pivotal single-arm study behind epcoritamab's approval; about half of complete responders are still in remission at three years.
EPCORE NHL-1, trial NCT03625037 sponsored by Genmab and AbbVie and reported in 2022, was the pivotal single-arm study behind epcoritamab's approval in relapsed or refractory large B-cell lymphoma after at least two lines, and about half of complete responders remain in remission at three years. In the 157-patient expansion cohort the objective response rate was 63 percent with complete responses in 39 percent, cytokine release syndrome occurred in about half but was rarely severe, and the three-year follow-up found many complete responders with undetectable circulating tumour DNA. Without a randomised comparison, and with the confirmatory EPCORE DLBCL-1 missing its US survival endpoint, whether the drug improves survival over chemotherapy is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Catherine Thieblemont, CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one, EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one, POLARGO, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares STARGLO, POLARGO, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma.